Due to a production error, the author affiliations were listed incorrectly, as “Junjie Teng1,2,†, Kai Zhou2,†, Dongxiao Lv2, Changshun Wu3,* and Hong Feng2,*” instead of “Junjie Teng1,2,†, Kai Zhou1,†, Dongxiao Lv1, Changshun Wu3,* and Hong Feng1,*”.
The publisher apologizes for this mistake. The original version of this article has been updated.
Summary
Keywords
ErbB2 mutation, afatinib, adenocarcinoma cell lung carcinoma, PTEN mutation, immunotherapy
Citation
Frontiers Production Office (2022) Erratum: Case report: PTEN mutation induced by anti-PD-1 therapy in stage IV lung adenocarcinoma. Front. Pharmacol. 13:1058178. doi: 10.3389/fphar.2022.1058178
Received
30 September 2022
Accepted
30 September 2022
Published
20 October 2022
Approved by
Volume
13 - 2022
Updates
Copyright
© 2022 Frontiers Production Office.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Production Office, production.office@frontiersin.org
This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Pharmacology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.